# A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

> **NCT05292898** · PHASE1 · TERMINATED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 10 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** LCAR-AIO Cells

## Key facts

- **NCT ID:** NCT05292898
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-14
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-03-31
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Achieve the proof of concept
- **Last updated:** 2025-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05292898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05292898, "A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05292898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*